Newsfiscal.ai
Needham Lowers Price Target on RxSight to $7 From $11, Keeps Buy Rating
· Published
Article summary
Needham & Co. has maintained its 'Buy' rating on RxSight, Inc. while reducing its price target for the company's stock from $11 to $7.
An excerpt from the original article.Analyzed by WAPE AI.
Preparing English content…


Comments —
Loading comments…